Real-time financial, economic, and global news with market-focused context and analysis.
Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.
3 E Network Technology Group Limited announced the completion of the initial system-level architecture specification for its next-generation customized AI storage controller and preliminary validation of its core data flow algorithms through software simulation. This progress marks a key step in the development of hardware designed to overcome Inpu…
China’s central bank said it will keep policy appropriately loose and stand ready to introduce practical measures when necessary, while not explicitly committing to cuts in policy rates or the reserve-requirement ratio. The People’s Bank of China (PBoC) pledged to use existing tools, plan additional steps, step up counter-cyclical adjustment and wo…
Rocket Lab (RKLB) is priced for growth more than profits. With record top-line momentum (Q2 revenue of $234M, ~62% YoY) and a $2.36B backlog, the company’s upcoming Neutron program milestones set the stage for margin expansion and, potentially, sustained profitability. This trade idea lays out a long entry around current levels with a clear stop an…
Legend Biotech's recent in vivo CAR-T readout and manufacturing expansion make its pipeline narrative real. Pair that with improving technicals and manageable financing, and there is a mid-term trade worth considering: enter on weakness, target the $30 area, and protect capital with a below-$18 stop.
A senior Iranian official says there have been no negotiations to prolong an interim ceasefire with the United States because Tehran views the agreement as having had no defined start date. The comment follows external reports that Tehran and Washington had agreed to extend a 60-day window under the June interim deal. Mediators are said to be discu…
Protagonist Therapeutics just cleared a major commercial hurdle with Icotyde (icotrokinra) approval and a $50M milestone payment; the stock still offers upside as the market reprices recurring-revenue potential and waits on rusfertide and other pipeline moves. This trade idea takes a long stance with a 180-trading-day horizon and a clear entry, sto…
Paramount Gold Nevada (PZG) has made measurable permitting progress at Grassy Mountain and picked up federal FAST-41 status, but audited filings with a going concern qualification and only ~$2.6M of cash leave the company exposed if capital markets turn cold. Technicals show an overbought setup while short activity has been meaningful — a setup tha…
Ming Shing Group Holdings Limited (NASDAQ: PMA), a Hong Kong-based company focused on wet trades works and graphene technology, announced entering into a stock purchase agreement to acquire Meals Through Seasons Limited, a company controlling MTHK which operates in organic agricultural supply chain, cold chain logistics, and product processing. The…
BrainsWay Ltd. reported a strong second quarter 2026 with revenue increasing 35% year-over-year to $17.1 million, a more than doubling of adjusted EBITDA to $3.5 million, and record shipments of Deep TMS systems up 42%. The company raised its full-year 2026 revenue guidance to $68-$70 million and adjusted EBITDA to $13-$14 million, citing expanding…
PolyPid Ltd. reports FDA acceptance with Priority Review for its NDA submission of D-PLEX100 aimed at preventing surgical site infections in abdominal colorectal surgeries. The FDA PDUFA goal date is set for November 28, 2026, ahead of prior guidance, with a potential commercial launch in early 2027 under an exclusive U.S. and Canada partnership wi…
Rekor Systems announced that their GoSecure platform now includes patent-pending audio verification capabilities, applying cryptographic authentication to audio recordings. This extends their technology beyond video to meet growing demands from law enforcement, courts, financial institutions, and government agencies for verifiable and tamper-proof …
Altimmune, Inc. announced key advancements in its late-stage clinical program for pemvidutide, targeting metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company initiated a global Phase 3 PERFORMA trial in MASH, reported positive Phase 2 topline data in AUD, and co…
Arbutus Biopharma reported a solid financial position at the end of Q2 2026, including receipt of a $178 million settlement payment from Moderna. The company filed international patent enforcement lawsuits against Pfizer and BioNTech related to its lipid nanoparticle technology. It also obtained FDA Fast Track designation for imdusiran, its hepatit…
Nexxen announced key executive appointments including Chance Johnson as President, Kara Puccinelli as Chief Commercial Officer, and Kenneth Suh as Chief Business Officer to strengthen leadership as the company scales its AI-powered unified advertising platform. These appointments aim to enhance strategic client relationships, expand enterprise grow…
Nexxen International Ltd. reported record second quarter 2026 financial results, with Contribution ex-TAC of $97.8 million and programmatic revenue of $95.2 million, reflecting double-digit year-over-year growth. The company achieved an all-time record for quarterly Connected TV (CTV) revenue, up 33% year-over-year. Nexxen advanced its AI technolog…
Xilio Therapeutics announced FDA clearance of its IND application for XTX501, a bispecific PD-1/masked IL-2 therapy targeting solid tumors. The company is advancing additional masked T cell engager programs with anticipated IND submissions in 2027. Q2 financials showed increased collaboration revenue and reduced net loss, with a strong cash runway …
Adagene Inc. announced its financial results for the six months ended June 30, 2026, highlighting significant clinical advancements in its lead candidate muzastotug (ADG126), a masked anti-CTLA-4 antibody. The company reported encouraging efficacy and safety data in microsatellite stable colorectal cancer (MSS CRC) and hepatocellular carcinoma (HCC…
Unicycive Therapeutics announced its Q2 2026 financial results and provided a business update highlighting progress toward FDA approval of its lead drug candidate, oxylanthanum carbonate (OLC), for treating hyperphosphatemia in dialysis patients. The FDA has assigned a facility inspection to the third-party manufacturer, a prerequisite for NDA resu…
Polar Power, Inc. announced $7.9 million in revenue from the Pacific Islands since 2024, driven by 333 shipments of DC power and solar-hybrid systems to countries including Papua New Guinea and Fiji. Repeat orders from telecommunications customers indicate growing adoption and reliability of its technology. The company is now expanding into adjacen…
Electra Battery Materials Corporation announced the appointment of Peter Rawlins as its new CFO, effective August 26, 2026, bringing extensive mining finance and capital markets experience. The company reported Q2 2026 financial results showing progress in the construction of North America's first cobalt sulfate refinery in Ontario, with constructi…
Milestone Pharmaceuticals announced Q2 2026 financial results and corporate updates, reporting increased patient and prescriber adoption of its FDA-approved cardiovascular drug CARDAMYST for PSVT, expanded insurance coverage to over 50% of commercially insured lives in the U.S., and initiation of a Phase 3 registrational trial for atrial fibrillati…
Alterity Therapeutics announced the granting of a new U.S. composition of matter patent for its lead clinical drug candidate ATH434. This patent extends protection until at least 2045, significantly increasing ATH434's commercial value and underpinning the planned initiation of Phase 3 trials in Multiple System Atrophy by the end of 2026. The stren…
Kamada Ltd., a global biopharmaceutical company specializing in specialty plasma-derived therapies, announced record-high revenues and adjusted EBITDA for the first half and second quarter of 2026, driven by strong sales growth of its proprietary products like KEDRAB in the U.S., VARIZIG, and HEPAGAM. The company affirmed its 2026 annual financial …
TScan Therapeutics reported second quarter 2026 financial results and corporate updates highlighting the dosing of the first patient in the Phase 3 ALLOHA-2 study evaluating their lead TCR-T therapy candidate TSC-101. Positive initial data from the Phase 1 ALLOHA study validated their commercial-ready manufacturing process. The company has a health…
Perma-Fix Environmental Services, Inc. has been awarded a Master IDIQ subcontract by Hanford Tank Waste Operations & Closure, LLC for the treatment and disposal of pretreated liquid mixed low-level waste from the DOE's Hanford Site. The subcontract is effective from August 2026 with task orders expected to begin in 2027, running through 2041. The w…
